Table 1 : Cytogenetic results.


Analysis

Specimen G banding FISH ***(% +)

*# Date Type (number of cells in brackets) --
#1 08/05/10 **BM 46,XX, del(5)(q12q33)[11]/46 XX[8] del(5)(q31)/(18.5%)

#2 06/06/14 ****UB 45,XX,t(9;15;22)(q34;p10;q11.2),-22[20] del(5)(q31)/(1.5%)
BCR/ABL1 + (100% metaphases)

#3 07/11/14 UB 45,XX, t(9;15;22)(q34; p10; q11.2),-22[12]
/46,XX,t(9;15;22)(q34; p10; q11.2),+der (15),
t(9;22)(q34;q11.2),-22[3]
BCR/ABL1 +/(93%)
Extra BCR/ABL1+ (3% metaphases)
extra der(15)t(9;15;22)(q34; p10;q11.2) (30% metaphases)

#4 07/21/14 UB 45, XX, t(9;15;22)(q34;p10;q11.2),-22[15]
/46,XX,t(9;15;22)(q34;p10;q11.2),
+der(15)t(9;15;22)(q34;p10;q11.2),-22[5]
BCR/ABL1 + 100%
Extra BCR/ABL1+/(5.5%)
[an extra der(15)t(9;15;22)(q34;p10;q11.2)]
(10% of metaphases)

#5 11/14/14 BM 45, XX, t(9;15;22)(q34;p10;q11.2),-22[6]
/46,XX,t(9;15;22)(q34;p10;q11.2),+der(15)
t(9;15;22)(q34;p10;q11.2),-22[1]
/46,XX,t(9;15;22)(q34;p10;q11.2),
der(22)t(9;22)(q34;q11.2)[1]
/45,XX,del(5)(q12q33)[1]
/46,XX[11]
del(5)(q31)(0.5%)
BCR/ABL1 +/(41% metaphases)

#6 4/24/15 UB No chromosomes
(no growth)
del(5)(q31)(0.5%)
3 copies of ABL1(16%)
1 copy BCR/ABL1/(7.5%)

#7 7/22/15 BM 47,XX,+8[CP5]/46,XX[7] +8(5%)
+9(6%)
Normal BCR/ABL1 and 5q

#8 11/16/15 BM • 42~46,XX,der(5)t(5;?)(p15;?),-7,-9,
t(9;22)(q34;q11.2),-15,der(22)t(9;22)(q34;q11.2)
t(15;22)(q23;q11.2)[cp9]
•• //46,XY[11]
• XX (56%), del(5)(q31) (1%)
• BCR/ABL1 (22.5%)
• der(22)t(15;22)(q23;q11) (100%)
•• XY (44%)

#9 1/27/16 BM •45~46,XX,der(5)t(5;?)(p15;?),t(9;22)(q34;q11.2),
15,der(22)t(9;22)(q34;q11.2)t(15;22)
(q23;q11.2)[cp2]
/46,XX[14]
•• //46,XY[4]
• XX (69%), del(5)(q31) (1.5%)
• BCR/ABL1 (1.5%)
•• XY (30.5%)
Normal 8 (100%)

*# –Number; **BM – Bone Marrow; ***% + –Percent Positive; ****UB –Unstimulated Blood •–Patient karyotype and FISH; •• –Donor karyotype and FISH

Zaslav et al.Hematology and Leukemia  2016 4:2DOI : 10.7243/2052-434X-4-2